KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Assets: 2017-2025

Historic Other Non-Current Assets for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $39.5 million.

  • Amneal Pharmaceuticals' Other Non-Current Assets rose 8.78% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 8.78%. This contributed to the annual value of $60.1 million for FY2024, which is 8.31% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Other Non-Current Assets stood at $39.5 million, which was down 12.02% from $44.8 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Other Non-Current Assets registered a high of $108.3 million during Q3 2022, and its lowest value of $19.2 million during Q2 2021.
  • Its 3-year average for Other Non-Current Assets is $63.7 million, with a median of $60.1 million in 2024.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 454.39% in 2022, then tumbled by 59.26% in 2024.
  • Amneal Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $20.6 million in 2021, then spiked by 400.71% to $103.2 million in 2022, then slumped by 46.21% to $55.5 million in 2023, then grew by 8.31% to $60.1 million in 2024, then increased by 8.78% to $39.5 million in 2025.
  • Its Other Non-Current Assets stands at $39.5 million for Q3 2025, versus $44.8 million for Q2 2025 and $45.4 million for Q1 2025.